Resources

The Amazon Alexa voice assistant is now offering UK users expert NHS health advice, with the aim of improving the quality of public health information and reducing demand on the overstretched health service. The smart home device will now automatically search and...

Look into multiplexing The lateral flow test market is a large and growing faction of the overall diagnostics market, worth an estimated $6bn in 2018, and is projected to reach $8.7bn in 2023. More than two billion lateral flow assays are produced...

Parexel shut down a San Diego office back in April as three workers were axed and 37 others were offered work-from-home jobs.

Medial EarlySign has partnered with Geisinger and its Steele Institute for Health Innovation to develop new machine learning-based solutions for the identification of people at risk of chronic and high-burden diseases. EarlySign develops artificial intelligence (AI)...

Medical technology company Hillrom has agreed to divest select surgical consumable products and related assets to an Audax Private Equity affiliate for $170m. The surgical consumable products include Bard-Parker conventional and safety scalpels and blades, along with...

Digital therapeutics firm Neurolief has secured the European CE-Mark to market, sell and distribute its Relivion device as a digital migraine treatment. Relivion has been developed as a non-invasive, multi-channel brain neuromodulation technology that is said to...

The Trump administration has put forward an executive order designed to incentivize at-home kidney dialysis, potentially affecting tens of thousands of people who undergo the procedure at commercial clinics.

Michael Becker, the former biotech CEO who spent his life working on new drugs and then turned to raising awareness of the cancer that would eventually kill him, has died of head and neck cancer that had spread to his lungs.

23andMe’s chief scientific officer and former therapeutics foreman Richard Scheller has left the sequencing company and landed on the boards of at least two biotechs—namely, two of the biggest money raisers of the year so far.

Last month, he was the chief executive of struggling Merrimack; today, he’s the new CEO at Fierce 15 winner and early-stage biotech Yumanity as Sanofi Genzyme veteran Richard Peters looks to move on.

The field of biotechs developing treatments for Duchenne muscular dystrophy became more crowded this week, with biotech startup Dyne setting its sights on the muscle-wasting rare disease. Read more. The post Undeterred by Vertex’s plans, biotech Dyne enters...

Akrevia Therapeutics is on a mission to make immunotherapies safer. The startup, based in the LabCentral incubator in Cambridge, Mass., is working on drug candidates that act much like therapies that are already on the market, including Bristol Myers-Squibb’s...

Synlogic, a developer of so-called “living medicines” comprised of engineered bacteria, is teaming up with synthetic biology company Ginkgo Bioworks in an effort to advance drug candidates to human testing more quickly. Read more. The post Synlogic Lands...

Open-source design and programming could accelerate scientific advances by offering a unified platform to fragmented research efforts across the field of prosthetics.

Project expands use of artificial intelligence in biomedical engineering.

Powerbox’s dc-dc converters feature a typical leakage current of 2 µA and 5000-V ac isolation voltage.

It’s critical that those designing medical-devices know the pros and cons of the wide variety of skin-compatible adhesives available.

As contestants of this annual programming competition demonstrate, developing embedded software with Ada is easier than you think.

I am the CEO of Synlogic, a synthetic biology company, where the focus of our work is the development of medicines using engineered bacteria. I love the science of what we do; it is challenging, innovative and has the potential to make a really big impact for...

At Spero we are privileged to be enrolling our pivotal study for SPR994, our oral antibiotic with the bacteria-killing power of an IV to treat patients with serious urinary tract infections.  A frightening sign of our deteriorating antibiotic arsenal is the three...

Gary Pisano’s recent Harvard Business Review piece, The Hard Truth About Innovative Cultures, beautifully frames up how innovative corporate environments are frequently misunderstood. Innovative startups aren’t just about being cool and nimble, having beer taps in the...

As a follow up to this year’s Heart Rhythm conference in San Francisco, Lars Thording of Innovative Healthcare, an AMDR member, blogs his 4 takeaways from the meeting.  This was the 40th annual Heart Rhythm Scientific Sessions and both AMDR members...

Healthcare Purchasing News Blog: Advancements in electrophysiology continue but with few solutions to reduce costs Lars Thording of Innovative Healthcare gives his  Take-aways from the 2019 Heart Rhythm Society’s 40th Annual Scientific Sessions …The...

Vertex Pharmaceuticals is paying $70 million upfront to work with Kymera Therapeutics on the discovery of drugs that drive the elimination of disease-causing proteins. The early-stage deal features more than $1 billion in milestones tied to the success of six...

Translation of well validated biology into therapeutics remains one of the biggest challenges of modern drug development, in many cases due to lack of appropriate technologies to drug well credentialed biological targets. Examples in this category include driver...